These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8044415)

  • 1. The properties of HDL in genetically engineered mice.
    Schultz JR; Rubin EM
    Curr Opin Lipidol; 1994 Apr; 5(2):126-37. PubMed ID: 8044415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice.
    Zhong S; Goldberg IJ; Bruce C; Rubin E; Breslow JL; Tall A
    J Clin Invest; 1994 Dec; 94(6):2457-67. PubMed ID: 7989603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II.
    Warden CH; Hedrick CC; Qiao JH; Castellani LW; Lusis AJ
    Science; 1993 Jul; 261(5120):469-72. PubMed ID: 8332912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism. Studies in transgenic mice.
    Hayek T; Azrolan N; Verdery RB; Walsh A; Chajek-Shaul T; Agellon LB; Tall AR; Breslow JL
    J Clin Invest; 1993 Sep; 92(3):1143-52. PubMed ID: 8376576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice.
    Schultz JR; Verstuyft JG; Gong EL; Nichols AV; Rubin EM
    Nature; 1993 Oct; 365(6448):762-4. PubMed ID: 8413656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies.
    Tall AR
    J Intern Med; 1995 Jan; 237(1):5-12. PubMed ID: 7830031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remodelling of high density lipoproteins by plasma factors.
    Rye KA; Clay MA; Barter PJ
    Atherosclerosis; 1999 Aug; 145(2):227-38. PubMed ID: 10488948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins.
    Rosales C; Gillard BK; Courtney HS; Blanco-Vaca F; Pownall HJ
    Biochemistry; 2009 Aug; 48(33):8070-6. PubMed ID: 19618959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linkage analysis of the genetic determinants of high density lipoprotein concentrations and composition: evidence for involvement of the apolipoprotein A-II and cholesteryl ester transfer protein loci.
    Bu X; Warden CH; Xia YR; De Meester C; Puppione DL; Teruya S; Lokensgard B; Daneshmand S; Brown J; Gray RJ
    Hum Genet; 1994 Jun; 93(6):639-48. PubMed ID: 8005588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic and genetic control of HDL cholesterol levels.
    Tall AR
    J Intern Med; 1992 Jun; 231(6):661-8. PubMed ID: 1619389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic mouse models of lipoprotein metabolism and atherosclerosis.
    Breslow JL
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8314-8. PubMed ID: 8378301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cholesterol ester transfer protein. A major player in cholesterol metabolism].
    Hansen PR
    Ugeskr Laeger; 1999 Sep; 161(38):5295-8. PubMed ID: 10536513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein A-II, HDL metabolism and atherosclerosis.
    Tailleux A; Duriez P; Fruchart JC; Clavey V
    Atherosclerosis; 2002 Sep; 164(1):1-13. PubMed ID: 12119188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis.
    Hughes SD; Verstuyft J; Rubin EM
    Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1725-9. PubMed ID: 9327769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein.
    Yamashita S; Hirano K; Sakai N; Matsuzawa Y
    Biochim Biophys Acta; 2000 Dec; 1529(1-3):257-75. PubMed ID: 11111094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels.
    Hayek T; Chajek-Shaul T; Walsh A; Agellon LB; Moulin P; Tall AR; Breslow JL
    J Clin Invest; 1992 Aug; 90(2):505-10. PubMed ID: 1644921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol homeostatic mechanisms in transgenic mice with altered expression of apoproteins A-I, A-II and A-IV.
    Kalopissis AD; Chambaz J
    Int J Tissue React; 2000; 22(2-3):67-78. PubMed ID: 10937356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes.
    Jiang X; Francone OL; Bruce C; Milne R; Mar J; Walsh A; Breslow JL; Tall AR
    J Clin Invest; 1996 Nov; 98(10):2373-80. PubMed ID: 8941656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
    Maïga SF; Kalopissis AD; Chabert M
    Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.